|
|
||||||||
Clinical Investigation |
1 Division of Diagnostic Imaging, M.D. Anderson Cancer Center, Houston, Texas; and 2 Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas
Correspondence: For correspondence or reprints contact: John F. Bruzzi, Division of Diagnostic Imaging, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 57, Houston, TX 77030-4009. E-mail: jbruzzi{at}mdanderson.org
Our objective was to evaluate the accuracy of PET/CT for the diagnosis of Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma. Methods: A retrospective study was performed of 37 patients with CLL who underwent 18F-FDG PET/CT at our institution between March 2003 and July 2005. All PET/CT scans were reviewed in consensus by 2 diagnostic radiologists. Sites of abnormal 18F-FDG uptake with a maximum standardized uptake value (SUVmax) of greater than 5 were considered highly suggestive of Richter's transformation. The PET/CT findings were correlated with histologic findings from bone marrow or lymph node biopsy performed within 6 wk of PET/CT and with clinical follow-up. Results: The 37 patients (26 men and 11 women; mean age, 61 y, range, 4082 y) underwent 57 PET/CT scans. In 10 (91%) of 11 patients with Richter's transformation, PET/CT detected sites of abnormal 18F-FDG uptake having an SUVmax of greater than 5. Richter's transformation was missed in 1 patient who had only low-grade 18F-FDG uptake (SUVmax < 5). Nine patients had false-positive PET/CT findings; in 3 of these patients, alternative malignancies were diagnosed (Hodgkin's disease; metastatic neuroendocrine carcinoma; nonsmall cell lung cancer). In all remaining patients, PET/CT correctly excluded Richter's transformation. For the specific diagnosis of Richter's transformation of CLL to diffuse large B-cell lymphoma, PET/CT had overall sensitivity, specificity, and positive and negative predictive values of 91%, 80%, and 53% and 97%, respectively. Conclusion: PET/CT can detect Richter's transformation of CLL to diffuse large B-cell lymphoma with a high sensitivity and a high negative predictive value.
Key Words: chronic lymphocytic leukemia Richter's transformation lymphoma PET PET/CT
This article has been cited by other articles:
![]() |
P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bodet-Milin, F. Kraeber-Bodere, P. Moreau, L. Campion, B. Dupas, and S. Le Gouill Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma Haematologica, March 1, 2008; 93(3): 471 - 472. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Tsimberidou, W. G. Wierda, W. Plunkett, R. Kurzrock, S. O'Brien, S. Wen, A. Ferrajoli, F. Ravandi-Kashani, G. Garcia-Manero, Z. Estrov, et al. Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia J. Clin. Oncol., January 10, 2008; 26(2): 196 - 203. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |